AI Drug Discovery for Pharma and Biotech

Drug discovery

1,083

papers

On emerging therapies

Overview

Rare cardiac tumors are predominantly primary malignancies like sarcomas (75% of cases) or lymphomas, with an incidence of ~34 per 100 million individuals [1][2][7]. Symptoms include heart failure, thromboembolism, or arrhythmias due to mass effect or invasion [1][3][6]. Diagnosis relies on advanced imaging (echocardiography, cardiac MRI/CT) and biopsy [6][15]. Prognosis is generally poor, but early resection of low-grade tumors or systemic therapy for lymphomas may improve outcomes [1][4][11].

Population

  • Incidence ~0.0017–0.028%, with sarcomas most common. Median age at diagnosis is 50 years, with slight female predominance [1][2][7].

Burden

  • Median survival ≤12 months for sarcomas vs. >40% 5-year survival for lymphomas [1][7][11].

  • High perioperative mortality and recurrence rates; 50% die within 1 year of diagnosis [2][4][16].

Therapies

  • Complete surgical resection when feasible (curative for localized tumors) [3][6][17].

  • Chemotherapy/radiation for lymphomas; limited efficacy in sarcomas [8][11].

  • Emerging approaches: Stereotactic radiotherapy (SBRT) and transapical radiofrequency ablation [3][13].

Categories: rare cardiac diseases, rare neoplastic diseases

Research Papers

1,083 drug discovery papers about Rare cardiac tumor. Recent publications:

1,083 drug discovery papers about Rare cardiac tumor. Recent publications:

categories:

Small molecules

small molecules
2026-09-14 | [A case of paraganglioma-related catecholamine-induced cardiomyopathy manifesting as dilated cardiomyopathy and literature review].

Paraganglioma (PGL) are rare, catecholamine-secreting neuroendocrine neoplasms arising from the adrenal medulla or the extra-adrenal paraganglionic system. Excessive secretion of catecholamines by PGL can induce myocardial damage, leading to catecholamine-induced cardiomyopathy (CICM). Some CICM presents morphologically as a dilated cardiomyopathy (DCM) phenotype. Its clinical identification and differential diagnosis are highly challenging, necessitating a comprehensive evaluation that integrates biochemical testing and multimodality imaging. Treatment strategies require a precise balance among endocrine regulation, heart failure management, and tumor intervention, relying heavily on multidisciplinary team collaboration. This article reports a case of PGL-associated CICM presenting with DCM and reviews the clinical diagnostic and therapeutic essentials as well as recent research progress regarding this condition. This case suggests that brown adipose tissue activation on 18F-FDG PET/CT may serve as a key clue to catecholamine excess; in patients with unexplained DCM/heart failure with reduced ejection fraction plus a retroperitoneal mass, nocturnal hypertension, or hypermetabolic symptoms, screening for PGL should be initiated promptly, followed by a perioperative pathway integrating α-blockade, volume optimization, delayed β-blockade, and guideline-directed anti-remodeling therapy for heart failure.

Open article ↗



2026-09-13 | Case Report: Leiomyosarcoma of the inferior vena cava presenting as a right atrial mass: the value of multimodality imaging.

Leiomyosarcoma of the inferior vena cava (IVC) is a rare malignant tumor that may extend into the right atrium and mimic a primary cardiac neoplasm. Because clinical presentation is often non-specific and depends on tumor location and extent, diagnosis may be delayed, particularly in acute settings with suboptimal imaging conditions. We report the case of a 33-year-old woman presenting with progressive dyspnea, ascites and peripheral edema consistent with right-sided heart failure. Initial contrast-enhanced computed tomography, performed to exclude pulmonary embolism, suggested a right atrial myxoma. However, stepwise multimodality imaging including transthoracic and transesophageal echocardiography, multiphasic computed tomography (CT), and cardiac magnetic resonance imaging (CMR) revealed a large intravascular mass originating from the IVC with contiguous extension in the right atrium, causing near-complete luminal obstruction of atrium and IVC. CMR was essential in establishing the diagnosis by demonstrating tumor continuity, tissue heterogeneity, and malignant enhancement patterns. Histopathological analysis confirmed a low-grade spindle cell leiomyosarcoma (G2, Ki-67 approximately 40%). Staging with multiphasic CT and magnetic resonance imaging of the brain excluded distant metastases. The patient was initiated on neoadjuvant chemotherapy with doxorubicin and ifosfamide with planned surgical resection. This case illustrates the importance of multimodality imaging, with CMR playing a central role, in distinguishing malignant intravascular tumors from benign intracardiac masses. Early diagnosis and a multidisciplinary approach are essential for optimal management.

Open article ↗



2026-08-29 | Case report: primary cardiac lymphoma presenting as acute coronary syndrome and atrioventricular block due to right coronary artery compression.

Cardiac tumours are exceedingly rare and often present with non-specific clinical manifestations, making diagnosis challenging. Primary cardiac lymphoma represents a small proportion of primary cardiac tumours and may occasionally mimic acute coronary syndromes due to mass effect on coronary arteries or the conduction system. We report the case of a 61-year-old woman admitted for syncope who subsequently developed chest pain, inferior ST-segment elevation myocardial infarction, and complete atrioventricular block. Emergency coronary angiography revealed no obstructive coronary disease but demonstrated extrinsic compression and stiffness of the right coronary artery. Transthoracic echocardiography identified a large right ventricular mass with tricuspid valve involvement and right ventricular inflow obstruction, associated with pericardial and pleural effusion. Multimodality imaging with computed tomography and positron emission tomography showed a large hypermetabolic cardiac mass with mediastinal lymphadenopathy. Histological analysis from a computed tomography-guided biopsy confirmed primary cardiac high-grade B-cell lymphoma. Chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone was initiated, leading to significant tumour reduction but complicated by transient chemotherapy-induced left ventricular dysfunction, which was managed through a multidisciplinary cardio-oncology approach. Despite initial clinical and cardiac improvement, the patient later developed central nervous system progression and died 10 months after diagnosis due to therapy-related neurotoxicity. This case highlights a rare presentation of primary cardiac lymphoma manifesting as acute coronary syndrome and atrioventricular block secondary to extrinsic coronary compression. It underscores the importance of multimodality imaging, histological confirmation, and adherence to European Society of Cardiology cardio-oncology guidelines. Early multidisciplinary management is essential to balance effective oncological treatment with cardiovascular safety.

Open article ↗



2026-08-27 | Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis.

Primary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We aimed to analyze diagnostic pathways and factors influencing survival. A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420261277326). MEDLINE, Web of Science, and EMBASE were searched up to March 2025. Case reports and case series published from 2010 onwards de- scribing histologically confirmed PPM were included. Data were extracted independently by multiple reviewers. Risk of bias was assessed using Joanna Briggs Institute tools. Individual patient data were pooled. Survival was analyzed using Kaplan-Meier and log-rank tests, and factors associated with survival ≥12 months were evaluated using univariable logistic regression. A total of 120 patients were included (108 case reports, 4 case series). Diffuse pericardial involvement predominated (74.2%), while localized tumors occurred in 30.8%. Constrictive pericarditis was present in 31.7%. Median overall survival from diagnosis was 7.4 months (IQR 1.75-13.5). Use of CT and PET in the diagnostic process was associated with longer survival (CT: 9.1 vs. 1.5 months, p = 0.02; PET: 14 vs. 6 months, p = 0.04). Chemotherapy was associated with improved survival (OR 3.3; 95% CI 1.3-8.4; p = 0.01). Greater pericardial effusion volume was also associated with longer survival (OR 1.56; 95% CI 1.05-2.32; p = 0.028). Worse outcomes were observed in patients with constrictive pericarditis (p = 0.01) and diffuse disease (p = 0.04). PPM carries a poor prognosis. Chemotherapy and advanced imaging are associated with longer survival, whereas constrictive pericarditis and diffuse involvement indicate worse outcomes. Early recognition may reduce diagnostic delay. Findings should be interpreted with caution due to limitations of case-based data.

Open article ↗



2026-08-21 | Primary cardiac angiosarcoma mimicking minoxidil-related pericarditis: a case report.

Cardiac angiosarcoma, a rare and highly malignant primary cardiac tumour with poor prognosis, often presents diagnostic challenges owing to nonspecific clinical manifestations, with some cases initially presenting with acute pericarditis. Minoxidil, a commonly used treatment for androgenetic alopecia (AGA), has been associated with drug-induced pericarditis. A 23-year-old man with no significant medical history presented with chest pain at rest and pericardial effusion. The patient had been taking 5 mg/day of oral minoxidil for AGA; thus, drug-induced pericarditis was initially suspected. His symptoms improved with aspirin and colchicine. However, he experienced recurrent episodes of pericarditis. On the third presentation, echocardiography revealed cardiac tamponade, and pericardiocentesis showed haemorrhagic pericardial effusion with elevated tumour markers. Imaging studies supported the suspicion of a primary cardiac malignancy. Surgical biopsy confirmed the diagnosis of cardiac angiosarcoma. The patient underwent extensive tumour resection followed by adjuvant chemotherapy and proton beam therapy and was discharged without evidence of recurrence. However, metastatic recurrence subsequently developed, and he died 30 months after surgery. This case highlights the importance of considering malignancy in the differential diagnosis of recurrent pericarditis in young adults. Although minoxidil-related pericarditis was initially suspected, multimodal imaging and histopathological evaluation led to the diagnosis of cardiac angiosarcoma. Early identification and multidisciplinary management are essential in such rare presentations to improve patient outcomes.

Open article ↗



cell therapies
2026-06-22 | Mechanical forces of beating heart suppress cancer growth.

The cardiac vasculature is characterized by high pressure, high blood flow, and dense vascular branching, which may increase its exposure to circulating tumor cells (CTCs). However, both primary cardiac tumors and metastases are remarkably rare. This mechanism has remained poorly understood. A recent report by Ciucci and co-workers show that mechanical load in the heart inhibits cancer cell proliferation. Their work proposes that physiological mechanical stimuli is not merely a regulator of cancer progression, but also an intrinsic anticancer mechanism.

Open article ↗



2025-09-20 | Coincidence or Association?: Pacing for Sinus Node Dysfunction in a Newborn With a Giant Ventricular Rhabdomyoma.

Cardiac masses are rare in pediatric patients, and multimodality imaging is crucial for diagnosis. These masses can present with different arrhythmias, adding challenges to their management. We report an unusual presentation of cardiac masses in an infant with aborted sudden cardiac arrest, ST-segment elevation electrocardiography, and recurrent supraventricular tachycardia. The masses were distant from the sinoatrial node, yet we detected severe sinus node dysfunction requiring epicardial pacemaker implantation. Although the imaging suggested malignant features, tissue biopsy confirmed the diagnosis of benign rhabdomyoma. No other manifestations of tuberous sclerosis were detected. Several cases of this tumor were reported to present with arrhythmias. The management of these cases requires a multidisciplinary approach individualized for each patient. Infants with cardiac rhabdomyoma can experience severe sinus node dysfunction, irrespective of mass location, requiring pacing. Despite current advances in cardiac imaging, tissue biopsy is still the gold standard for accurate diagnosis.

Open article ↗



2025-09-15 | Durable response of primary cardiac lymphoma after autologous stem cell transplantation and sequential CAR-T therapy: a case report and literature review.

Primary cardiac lymphoma (PCL), an exceedingly rare and aggressive extranodal lymphoma confined to the heart and/or pericardium, poses significant diagnostic and therapeutic challenges with a historically dismal prognosis. We present the first documented case of PCL achieving sustained complete response (CR) through a novel therapeutic approach combining autologous hematopoietic stem cell transplantation (ASCT) with sequential tandem CD19/20 CAR-T therapy. A 55-year-old female presented with chest tightness and pericardial effusion in April 2023. The diagnostic process involved multiple modalities and analyses, culminating in a diagnosis via CT-guided mediastinal lymph node biopsy. The patient underwent several chemotherapy regimens, including combinations of rituximab and polatuzumab vedotin, R-CHOP, Pola-R-CHP, and Pola-R-DA-EPOCH, which led to symptom relief and partial response. Subsequently, ASCT was performed, followed by sequential tandem CD19/20 CAR-T therapy. As a maintenance treatment, the PD-1 inhibitor sintilimab was administered approximately every two months. The patient achieved CR at month 3 and maintained CR for one year following the CAR-T infusion. Following CAR-T therapy, the patient developed immune effector cell-associated hematologic toxicity, which was managed with granulocyte colony-stimulating factor injection and supportive care. This case illustrates the difficulties in diagnosing and treating PCL. Through the combination of ASCT and sequential tandem CD19/20 CAR-T therapy, the patient achieved sustained CR with manageable toxicity. This case demonstrates the feasibility, safety, and potential efficacy of this combination strategy in treating high-risk lymphoma. Moreover, we propose a structured algorithm that may help optimize the clinical implementation of CAR-T therapy in similar cases. Continued follow-up and broader studies are warranted to validate these findings.

Open article ↗



2025-01-31 | Resection of a cardiac lipoma and reconstruction wall of right atrium: A case report.

Cardiac lipomas are known to cause functional disturbances and symptoms by compressing adjacent tissues or organs, leading to potential complications such as dyspnea, palpitations, and cardiac arrhythmias. We report a case of a 52-year-old female with a large, well-circumscribed lipoma in the right atrium. This rare condition required a comprehensive diagnostic approach and therapeutic strategy for effective management. A 52-year-old female patient presented to the hospital with complaints of palpitations and fatigue lasting for 1 month, accompanied by the recent discovery of a cardiac mass via echocardiography over the past 2 days. In addition, she reported occasional episodes of a dry cough. Both echocardiography and cardiac computed tomography imaging revealed an isoechoic mass within the right atrium, characterized by a regular shape and close attachment to the right atrial wall, displaying noticeable mobility. Histopathological analysis following surgical intervention confirmed that the tumor was predominantly comprised of adipocytes. The patient underwent successful resection of the right atrial lipoma, followed by reconstruction of right atrium using a bovine pericardial patch under extracorporeal circulation with a beating heart. Postoperative recovery was complete, with resolution of symptoms including palpitations and fatigue. A follow-up echocardiogram on the 66th day postsurgery confirmed the absence of any residual tumor. Patients with small lipoma often remain asymptomatic. However, large or rapidly progressing tumors may elicit symptoms such as chest pain, dyspnea, and palpitations. For asymptomatic patients with small tumors, regular observation and follow-up are typically advised to monitor tumor growth and the emergence of symptoms. Conversely, patients with large tumors or overt symptoms should be recommended for prompt surgical intervention. In this case, preoperative anatomical evaluation for the lipoma involves the right atrial free wall, which is crucial to prevent excessive resection, damage to the lateral bundle branch, and subsequent postoperative cardiac dysfunction or arrhythmia, as exemplified in this patient.

Open article ↗



2024-05-29 | Incidental diagnosis of cardiac fibroma in an infant with acute viral bronchiolitis.

Pediatric cardiac tumors are rare and, among them, 90% are benign. Cardiac fibroma is the second most frequent tumor, after rhabdomyoma. The objective of this study is to report a case of cardiac fibroma diagnosed incidentally in a patient admitted with acute viral bronchiolitis. A 5-month-old male infant was admitted to the pediatric emergency department with acute viral bronchiolitis requiring hospitalization. He presented a detectable respiratory syncytial virus in oropharyngeal swab, blood test with lymphocytosis and a chest radiography revealed cardiomegaly. Further cardiologic testing was performed detecting elevation of cardiac biomarkers, an electrocardiogram with alteration of left ventricular repolarization and echocardiogram with a heterogeneous mass in the left ventricular, with areas of calcification. A chest angiotomography suggested rhabdomyosarcoma or cardiac fibroma and a magnetic resonance showed a mass, with characteristics suggesting fibroma. The final diagnosis was made after two cardiac catheterizations for biopsy of the lesion, confirming cardiac fibroma by anatomopathological examination. Because the patient had moderate to severe systolic dysfunction, he was submitted to heart transplant. One third of cardiac fibromas are asymptomatic, generally diagnosed late through tests ordered for other reasons. The gold-standard test for definitive diagnosis is biopsy. Cardiac fibroma usually does not present spontaneous regression and, in most cases, partial or total surgical resection is necessary. When tumors are unresectable, heart transplantation should be indicated. It is essential to have detailed characterization of the cardiac mass to establish the most appropriate therapeutic approach for each patient. Tumores cardíacos pediátricos são raros e, entre eles, 90% são benignos. O fibroma cardíaco é o segundo mais frequente, após o rabdomioma. O objetivo deste trabalho é relatar um caso de fibroma cardíaco, cujo diagnóstico foi incidental em um paciente internado por bronquiolite viral aguda. Lactente do sexo masculino com cinco meses foi atendido em um pronto atendimento pediátrico com quadro de bronquiolite viral aguda, necessitando de hospitalização. Em exames complementares, apresentou vírus sincicial respiratório detectável, hemograma com linfocitose, além de radiografia de tórax com cardiomegalia. Em investigação cardiológica, as enzimas cardíacas encontravam-se elevadas, o eletrocardiograma apresentava alteração de repolarização de parede lateral de ventrículo esquerdo e o ecocardiograma demonstrou massa heterogênea em ventrículo esquerdo, com áreas de calcificação. A angiotomografia de tórax sugeriu rabdomiossarcoma ou fibroma cardíaco e a ressonância magnética demonstrou massa cuja localização e características sugeriram fibroma. O diagnóstico foi conclusivo após dois cateterismos para biópsia da lesão, confirmando fibroma cardíaco pelo anatomopatológico. Em razão da disfunção sistólica moderada a grave, o paciente foi submetido a transplante cardíaco. Um terço dos fibromas cardíacos é assintomático, geralmente diagnosticado tardiamente por meio de exames solicitados por outro motivo. O padrão-ouro para o diagnóstico definitivo é a biópsia. O fibroma cardíaco não costuma apresentar regressão espontânea, sendo submetido, na maioria dos casos, a ressecção cirúrgica parcial ou total. Nos tumores irressecáveis, o transplante cardíaco deve ser indicado. A caracterização detalhada da massa cardíaca é fundamental para traçar a conduta terapêutica mais adequada para cada paciente.

Open article ↗



proteins
2026-08-26 | Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis.

Immune checkpoint inhibitor (ICI) myocarditis is a rare but frequently fatal immune-related adverse event of cancer immunotherapy. Understanding the mechanisms of this toxicity is critical to balancing treatment with maintenance of antitumor immunity. Using integrated spatial and single-cell analyses in a pharmacological murine model, we identified regional infiltration of Ly6C+ monocytes and PD-1+ CD8+ T cells in the heart that organize into fibroblast-rich immune structures, which we term tertiary T cell niches (TTCNs). TTCNs serve as hubs for T cell activation, sharing features of tertiary lymphoid structures. A TTCN gene signature was strongly enriched in cardiac tissue from patients with ICI myocarditis. Complementary T cell receptor analyses revealed clonal expansion of cardiac T cells following ICI treatment. We further identified TTCN-associated cytokines and structural proteins as candidate therapeutic targets to reduce myocardial inflammation while considering tumor control. Together, these findings suggest that cardiac tertiary immune structures play a central role in ICI myocarditis and highlight pathways that could mitigate ICI cardiotoxicity.

Open article ↗



2026-08-25 | BIN1 overexpression rescues cardiac but not skeletal muscle defects in a mouse model of caveolinopathy.

Mutations in CAV3, encoding caveolin-3, cause caveolinopathies, rare genetic disorders affecting both skeletal and cardiac muscle. Caveolin-3 contributes to T-tubule formation and excitation-contraction coupling. To date, there are no therapy for caveolinopathies. BIN1 (amphiphysin 2), a membrane-shaping protein critical for T-tubule integrity, has shown therapeutic promise in congenital myopathies and heart dysfunction. We evaluated the therapeutic impact of BIN1 overexpression in Cav-3 knockout mice, a model recapitulating key features of human caveolinopathy. We assessed skeletal and cardiac function, T-tubule morphology, mitochondria, and gene expression using histological, physiological, and molecular approaches. Results: We found Cav-3-/- mice displayed skeletal muscle weakness, T-tubule disorganization, and mitochondrial abnormalities, alongside cardiac diastolic dysfunction and myofibrillar disarray. While BIN1 overexpression failed to improve muscle strength, T-tubule structure, or fiber atrophy, it corrected nuclear positioning and partially restored mitochondrial markers in skeletal muscle. In contrast, BIN1 robustly rescued cardiac performance, restoring end-diastolic volume, cardiac output, and sarcomeric integrity. Expression profiling revealed greater dysregulation of excitation-contraction coupling and atrogene pathways in skeletal than in cardiac muscle in Cav-3-/- mice. Cavin-4, a BIN1-interacting protein and caveolar component, was selectively dysregulated in Cav-3-/- muscle, suggesting a mechanistic barrier to BIN1-mediated rescue in this tissue. These findings identify tissue-specific differences in the molecular consequences of caveolin-3 loss and demonstrate that BIN1 overexpression effectively rescues cardiac manifestations of caveolinopathy while only partially ameliorating the associated subcellular defects in skeletal muscle. Our results support BIN1 investigation as a potential target for inherited cardiomyopathies, while highlighting the need for alternative strategies in skeletal muscle.

Open article ↗



2024-10-01 | 8120 Effective Management of Neonatal Hypercalcemia in Congenital Mesoblastic Nephroma: A Case Report on the Use of Calcitonin

Abstract Disclosure: C.S. Galvez: None. K. Rifai: None. C. Moorthy: None. S. Chheda: None. M. Zerah: None. Introduction: Pediatric patients with hypercalcemia of malignancy are typically treated with hyperhydration, loop diuretics and bisphosphonates. Calcitonin, a peptide functionally antagonizes the effects of PTH. Calcitonin has limited pharmacokinetic data in neonates, especially those with Congenital Mesoblastic Nephroma (CMN), making treatment challenging with unclear safety and efficacy parameters. We present the fourth published case describing the use of calcitonin for likely PTH-rP-mediated severe hypercalcemia in a neonate with CMN. Clinical Case: A 15-day-old late preterm male, presented with lethargy, poor feeds, severe failure to thrive and a large abdominal mass. The mother is a G4P4, with good prenatal care. On admission, the patient was hypertensive (138/84 mmHg) and appeared dehydrated. Physical examination revealed a firm mass in the right abdomen crossing the midline. Serum calcium levels were 13.5 mg/dL (normal 9.0-10.9 mg/dL), with an ionized calcium 1.71 mmol/L (normal 1.15 and 1.30 mmol/L). Abdominal ultrasound showed a large, 9.1 x 8 cm dominant solid right renal mass, most likely CMN, with left-sided medullary nephrocalcinosis. Cardiac Echo and EKG were within normal limits. The patient received hydration, nicardipine (titrated to decrease blood pressure by 10-15 mmHg per day) and furosemide at 1 mg/kg/day IV q6h. Due to the persistence of hypercalcemia after 24 hours of treatment (14.7 mg/dL serum calcium with ionize of 1.81 mmol/L), the patient received one dose of calcitonin (4 units/kg subcutaneously), resulting in a decrease in serum calcium to 11.5 mg/dL in 4 hours. The patient underwent a successful radical right uretero-nephrectomy, with post-surgery improvement of neurological, cardiovascular and electrolyte status. Unfortunately, PTH-rP sample was insufficient. Pathology reported CMN of the cellular type. CMN is a rare tumor with low malignant potential, representing approximately 3% of all pediatric renal tumors. It is the most common renal neoplasm diagnosed in the first 6 months of life. The most common symptom is an abdominal mass (76%), with hypertension (19%). Hypercalcemia was reported in only 4% which can be secondary to paraneoplastic secretion of PTH or PTH-rP. Conclusion: This case represents the fourth instance of calcitonin use in a neonate with CMN to manage persistent hypercalcemia. Subcutaneous administration of calcitonin at 4 units/kg proved effective with a short onset of action (within 2 hours) and duration of 6 to 8 hours, making it a viable alternative to bisphosphonates (action around 48 hours and duration of 7 to 14 days). Calcitonin's advantages include less significant side effects and a faster resolution of complications like "Hungry bone Syndrome." The flexibility of repeated dosing every 6 hours, with the option to increase the dose, if necessary, adds to its clinical utility. Presentation: 6/3/2024

Open article ↗



2022-02-11 | Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report.

Primary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible. Available therapeutic modalities for metastatic disease include external beam radiation therapy as well as systemic treatments, namely 131I-MIBG and more recently, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. To our knowledge, this is the first case of progressive unresectable cardiac paraganglioma with intracardiac extension treated with dosimetry based personalized PRRT to be reported. This case is of particular interest since it documents for the first time the efficacy, and especially the safety of the 177Lu-DOTATATE PRRT in this precarious context for which therapeutic options are limited. A 47-year-old man with no medical history consulted for rapidly decreasing exercise tolerance. The investigation demonstrated an unresectable progressing metastatic cardiac paraganglioma with intracardiac extension. The patient was treated with personalized 177Lu-DOTATATE PRRT and showed complete symptomatic and partial anatomical responses, with a progression-free survival of 13 months. PRRT with 177Lu-DOTATATE should be considered for inoperable cardiac paraganglioma. No major hemodynamic complications were experienced. Therapy resulted in safety and substantially improved quality of life.

Open article ↗



2003-02-21 | The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.

The activation of cells that do not express the membrane bound interleukin-6 6 receptor (IL-6R) by IL-6 and the soluble IL-6 receptor (sIL-6R) is termed transsignalling. Transsignalling may be an pathogenetic factor in human diseases as diverse as multiple myeloma (MM), Castleman's disease, prostate carcinoma, Crohn's disease, systemic sclerosis, Still's disease, osteoporosis and cardiovascular diseases. IL-6 and sIL-6R may directly or indirectly enhance their own production on endothelial or bone marrow stromal cells. Positive feedback autocrine loops thus created in affected organs may either cause or maintain disease progression. In autoimmune or vasculitic disease, the ability of the IL-6/sIL-6R complex to inhibit apoptosis of autoreactive T-cells may be central to the development of tissue specific autoimmunity. The anti-apoptotic effect of the IL-6/sIL-6R complex may be involved in tumour genesis and resistance to chemotherapy. Only in rare cases, where counterregulation has failed, there is a notable systemic effect of IL-6/sIL-6R. Appropriate animal models are necessary to establish the pathogenetic role of the IL-6/sIL-6R complex. A specific treatment option for diseases influenced by the sIL-6R could be based on gp130-Fc, a soluble gp130 (sgp130) linked to the Fc-fragment of IgG1. gp130-Fc has shown efficacy in vivo in animal models of Crohn's disease.

Open article ↗



antibodies
2026-09-18 | Cardio-immuno-oncology in cardiac tumors and cardiac metastases: immune microenvironment, therapeutic opportunities, and cardiotoxicity

Primary cardiac tumors are rare, whereas cardiac metastases are more common forms of cardiac involvement in patients with advanced malignancies; both are clinically important because of their potential cardiovascular consequences. This review summarizes current evidence on the immune microenvironment, immune-evasion mechanisms, immunotherapeutic opportunities, multi-omics-based immune decoding, and cardiovascular toxicity in cardiac tumors and cardiac metastases. Cardiac myxoma is discussed as a benign primary cardiac tumor with inflammatory, cytokine-mediated, metabolic, and candidate immune-regulatory features, whereas malignant primary cardiac tumors, particularly cardiac sarcomas such as cardiac angiosarcoma, are reviewed in relation to immunosuppressive niches, macrophage-rich microenvironments, T-cell dysfunction, and heterogeneous responses to immune checkpoint inhibitors. Cardiac metastases are considered as a clinically relevant setting in which immunotherapy may be feasible for selected patients with careful cardiovascular assessment. Key mechanisms discussed include immune checkpoint pathways, tumor-associated macrophages, metabolic reprogramming, cytokine signaling, vascular abnormalities, and spatial immune organization. The review also highlights the role of single-cell sequencing, spatial transcriptomics, proteomics, metabolomics, and integrative multi-omics approaches in defining tumor-specific immune landscapes and potential biomarkers. Finally, immune checkpoint inhibitor-associated cardiotoxicity, particularly myocarditis, is discussed with emphasis on baseline cardiovascular assessment, biomarker monitoring, multimodality imaging, and multidisciplinary cardio-oncology management.

Open article ↗



2026-05-11 | A rare case of pediatric cardiac fibroma arising from the pulmonary valve and right ventricular outflow tract presenting with obstructive hemodynamics.

Primary cardiac tumors in the pediatric population are rare, and reports of cardiac fibromas diagnosed during childhood are limited. We report a pediatric case of cardiac fibroma attached to the right ventricular outflow tract (RVOT) and pulmonary valve that presented with RVOT obstruction in a 15-month-old boy who was referred for evaluation of a heart murmur. Echocardiography revealed a mobile 10-mm mass attached to the pulmonary valve that caused RVOT obstruction and elevated right ventricular pressure. Because of the risk of embolization and hemodynamic significance, surgical excision was performed. A pathological examination confirmed the diagnosis of cardiac fibroma. Although rare, pediatric cardiac tumors can cause serious complications such as embolism and arrhythmias, thus highlighting the importance of careful auscultation, detailed imaging evaluation, and appropriate surgical decision-making. Pediatric cardiac fibromas are rare and frequently asymptomatic; however, depending on their location and mobility, they may pose a significant risk of right ventricular outflow tract obstruction and embolic events. Careful cardiac auscultation, followed by timely echocardiographic assessment, is essential for early detection. Surgical intervention should be considered on the basis of hemodynamic impact rather than tumor size alone.

Open article ↗



2026-04-10 | Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee.

Thymic epithelial tumors (TETs), comprising thymomas, thymic carcinomas, and thymic neuroendocrine neoplasms, are rare prevascular (anterior) mediastinal malignancies characterized by histologic and clinical heterogeneity. Their management is complex because of overlapping pathologic features, variable clinical behavior, frequent associations with autoimmune conditions, and lack of standardized therapeutic algorithms. This review addresses current challenges across the diagnosis, management, and treatment of TETs. We outline diagnostic difficulties, including distinguishing TETs from histologic mimickers, and highlight the utility of immunohistochemical and molecular markers. Surgical considerations for early-stage disease are explored, debating thymomectomy versus complete thymectomy and optimal minimally invasive approaches, while also discussing the role of lymph node dissection and adjuvant therapy. Furthermore, this review delves into the evolving roles of immunotherapy and targeted therapy in TETs, acknowledging their potential while addressing challenges such as high rates of autoimmune disease recurrence and adverse events. The promising, albeit largely retrospective, applications of artificial intelligence in TETs, spanning diagnosis, target discovery, and prognostic modeling, are also explored as a critical area for future integration into clinical practice.

Open article ↗



2026-03-27 | An indolent course of undifferentiated pleomorphic cardiac sarcoma mimicking myxoma: A case report.

Cardiac undifferentiated pleomorphic sarcoma (UPS) is a rare and highly malignant tumor, commonly arising in the left atrium. It is associated with poor prognosis, nonspecific symptoms, and difficulty in early diagnosis. Here, we report a case of a 71-year-old woman who presented with palpitations, chest pressure, and exertional dyspnea, in whom initial cardiac magnetic resonance imaging revealed only subtle atrial septal thickening, evaluated as nonspecific, whereas follow-up imaging 2 years later showed progressive growth, ultimately interpreted as a cardiac myxoma. Surgical resection was performed, and histopathologic examination revealed a high-grade UPS with immunohistochemistry and molecular profiling supporting the diagnosis, including amplification of MDM2 and PDGFRA. No metastases were detected, and after multidisciplinary discussion a decision was made to abstain from adjuvant therapy. This case highlights the diagnostic challenge posed by cardiac UPS mimicking benign tumors such as myxoma on imaging and the importance of longitudinal imaging review and a high index of suspicion in cases with atypical radiological features of myxoma. It also raises awareness of an unusually indolent behavior of an UPS that otherwise pursues an aggressive course.

Open article ↗



2026-03-23 | Primary cardiac angiosarcoma with isolated superior vena cava syndrome: a case report.

Primary cardiac angiosarcoma is a rare and malignant tumor that most often arises in the right atrium causing significant inflow obstruction and circulatory disruption. Owing to its location, it is most often associated with symptoms similar to heart failure including lower extremity swelling, dyspnea, and chest pain. Other symptoms of venous congestion, including superior vena cava syndrome, are possible but symptoms vary widely depending on the location and size of the tumor and are rarely isolated. In this case, a 69-year-old Filipino American female presented to our facility with isolated findings of superior vena cava syndrome that were ultimately secondary to cardiac angiosarcoma. The patient developed recurrent pericardial effusions that necessitated drain placement. She was managed with medical, chemotherapeutic, and radiation therapy in the outpatient setting. She subsequently was found to have worsening of metastatic disease that resulted in her passing. Patients with cardiac angiosarcoma may present with atypical or nonspecific symptoms, such as with our patient presenting with isolated superior vena cava syndrome, and an atypical presentation may further delay the diagnosis. Late presenting cardiac angiosarcoma contributes to a worse prognosis and higher likelihood of metastasis at the time of diagnosis. Treatment typically includes chemotherapy and radiation but surgical excision, alone or in combination with other therapies, can provide the best prognosis. Early detection of cardiac angiosarcoma is crucial for improving outcomes.

Open article ↗



other
2024-11-29 | Cardiac myxomas: a review of current treatment approaches and emerging molecular therapies

Abstract Background Cardiac myxomas are the most common primary cardiac tumors, predominantly located in the left atrium. These benign tumors can obstruct blood flow, cause embolization, or produce systemic symptoms like fever. Diagnostic tools such as echocardiography play a critical role in their identification, while surgical resection remains the primary curative treatment. Although recurrence is rare, it occurs more frequently in patients with genetic predispositions, such as the Carney complex. The risk of life-threatening complications such as embolism and sudden death necessitates prompt diagnosis and management. Despite the success of surgical treatment, recent advances have introduced minimally invasive techniques and novel molecular therapies, particularly for recurrent cases. Main body The epidemiology of cardiac myxomas highlights their rarity, with an incidence of 0.5–1 per million individuals annually. They are classified based on location, morphology, and whether they are sporadic or syndromic. Histologically, they originate from multipotent mesenchymal cells and present as gelatinous or solid masses. The genetic implicants, especially in familial cases, involve certain gene mutations, disrupting signaling pathways and leading to tumorigenesis. Diagnosis primarily relies on imaging, with transthoracic echocardiography being the first-line modality. Surgical resection, typically via median sternotomy, remains the gold standard treatment with a low recurrence rate. However, emerging molecular therapies, including gene editing, epigenetic interventions, stem cell therapy, and immunotherapy, offer promising avenues for managing complex or recurrent cases even though they are mostly in conceptual and preclinical phases. These molecular approaches target specific genetic and signaling pathways involved in myxoma formation and recurrence, and though they remain in experimental stages, the advent of gene therapy in oncology makes them the next best choice to watch out for. Conclusions While surgical resection remains curative in most cases, recurrence, particularly in familial syndromes, requires vigilant monitoring and innovative treatments. Emerging molecular therapies show potential in offering personalized treatment options, although they are still inchoate. Further research is needed to improve delivery systems and minimize the challenges associated with these therapies, paving the way for more effective management strategies.

Open article ↗



small molecules
2026-09-14 | [A case of paraganglioma-related catecholamine-induced cardiomyopathy manifesting as dilated cardiomyopathy and literature review].

Paraganglioma (PGL) are rare, catecholamine-secreting neuroendocrine neoplasms arising from the adrenal medulla or the extra-adrenal paraganglionic system. Excessive secretion of catecholamines by PGL can induce myocardial damage, leading to catecholamine-induced cardiomyopathy (CICM). Some CICM presents morphologically as a dilated cardiomyopathy (DCM) phenotype. Its clinical identification and differential diagnosis are highly challenging, necessitating a comprehensive evaluation that integrates biochemical testing and multimodality imaging. Treatment strategies require a precise balance among endocrine regulation, heart failure management, and tumor intervention, relying heavily on multidisciplinary team collaboration. This article reports a case of PGL-associated CICM presenting with DCM and reviews the clinical diagnostic and therapeutic essentials as well as recent research progress regarding this condition. This case suggests that brown adipose tissue activation on 18F-FDG PET/CT may serve as a key clue to catecholamine excess; in patients with unexplained DCM/heart failure with reduced ejection fraction plus a retroperitoneal mass, nocturnal hypertension, or hypermetabolic symptoms, screening for PGL should be initiated promptly, followed by a perioperative pathway integrating α-blockade, volume optimization, delayed β-blockade, and guideline-directed anti-remodeling therapy for heart failure.

Open article ↗



2026-09-13 | Case Report: Leiomyosarcoma of the inferior vena cava presenting as a right atrial mass: the value of multimodality imaging.

Leiomyosarcoma of the inferior vena cava (IVC) is a rare malignant tumor that may extend into the right atrium and mimic a primary cardiac neoplasm. Because clinical presentation is often non-specific and depends on tumor location and extent, diagnosis may be delayed, particularly in acute settings with suboptimal imaging conditions. We report the case of a 33-year-old woman presenting with progressive dyspnea, ascites and peripheral edema consistent with right-sided heart failure. Initial contrast-enhanced computed tomography, performed to exclude pulmonary embolism, suggested a right atrial myxoma. However, stepwise multimodality imaging including transthoracic and transesophageal echocardiography, multiphasic computed tomography (CT), and cardiac magnetic resonance imaging (CMR) revealed a large intravascular mass originating from the IVC with contiguous extension in the right atrium, causing near-complete luminal obstruction of atrium and IVC. CMR was essential in establishing the diagnosis by demonstrating tumor continuity, tissue heterogeneity, and malignant enhancement patterns. Histopathological analysis confirmed a low-grade spindle cell leiomyosarcoma (G2, Ki-67 approximately 40%). Staging with multiphasic CT and magnetic resonance imaging of the brain excluded distant metastases. The patient was initiated on neoadjuvant chemotherapy with doxorubicin and ifosfamide with planned surgical resection. This case illustrates the importance of multimodality imaging, with CMR playing a central role, in distinguishing malignant intravascular tumors from benign intracardiac masses. Early diagnosis and a multidisciplinary approach are essential for optimal management.

Open article ↗



2026-08-29 | Case report: primary cardiac lymphoma presenting as acute coronary syndrome and atrioventricular block due to right coronary artery compression.

Cardiac tumours are exceedingly rare and often present with non-specific clinical manifestations, making diagnosis challenging. Primary cardiac lymphoma represents a small proportion of primary cardiac tumours and may occasionally mimic acute coronary syndromes due to mass effect on coronary arteries or the conduction system. We report the case of a 61-year-old woman admitted for syncope who subsequently developed chest pain, inferior ST-segment elevation myocardial infarction, and complete atrioventricular block. Emergency coronary angiography revealed no obstructive coronary disease but demonstrated extrinsic compression and stiffness of the right coronary artery. Transthoracic echocardiography identified a large right ventricular mass with tricuspid valve involvement and right ventricular inflow obstruction, associated with pericardial and pleural effusion. Multimodality imaging with computed tomography and positron emission tomography showed a large hypermetabolic cardiac mass with mediastinal lymphadenopathy. Histological analysis from a computed tomography-guided biopsy confirmed primary cardiac high-grade B-cell lymphoma. Chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone was initiated, leading to significant tumour reduction but complicated by transient chemotherapy-induced left ventricular dysfunction, which was managed through a multidisciplinary cardio-oncology approach. Despite initial clinical and cardiac improvement, the patient later developed central nervous system progression and died 10 months after diagnosis due to therapy-related neurotoxicity. This case highlights a rare presentation of primary cardiac lymphoma manifesting as acute coronary syndrome and atrioventricular block secondary to extrinsic coronary compression. It underscores the importance of multimodality imaging, histological confirmation, and adherence to European Society of Cardiology cardio-oncology guidelines. Early multidisciplinary management is essential to balance effective oncological treatment with cardiovascular safety.

Open article ↗



2026-08-27 | Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis.

Primary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We aimed to analyze diagnostic pathways and factors influencing survival. A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420261277326). MEDLINE, Web of Science, and EMBASE were searched up to March 2025. Case reports and case series published from 2010 onwards de- scribing histologically confirmed PPM were included. Data were extracted independently by multiple reviewers. Risk of bias was assessed using Joanna Briggs Institute tools. Individual patient data were pooled. Survival was analyzed using Kaplan-Meier and log-rank tests, and factors associated with survival ≥12 months were evaluated using univariable logistic regression. A total of 120 patients were included (108 case reports, 4 case series). Diffuse pericardial involvement predominated (74.2%), while localized tumors occurred in 30.8%. Constrictive pericarditis was present in 31.7%. Median overall survival from diagnosis was 7.4 months (IQR 1.75-13.5). Use of CT and PET in the diagnostic process was associated with longer survival (CT: 9.1 vs. 1.5 months, p = 0.02; PET: 14 vs. 6 months, p = 0.04). Chemotherapy was associated with improved survival (OR 3.3; 95% CI 1.3-8.4; p = 0.01). Greater pericardial effusion volume was also associated with longer survival (OR 1.56; 95% CI 1.05-2.32; p = 0.028). Worse outcomes were observed in patients with constrictive pericarditis (p = 0.01) and diffuse disease (p = 0.04). PPM carries a poor prognosis. Chemotherapy and advanced imaging are associated with longer survival, whereas constrictive pericarditis and diffuse involvement indicate worse outcomes. Early recognition may reduce diagnostic delay. Findings should be interpreted with caution due to limitations of case-based data.

Open article ↗



2026-08-21 | Primary cardiac angiosarcoma mimicking minoxidil-related pericarditis: a case report.

Cardiac angiosarcoma, a rare and highly malignant primary cardiac tumour with poor prognosis, often presents diagnostic challenges owing to nonspecific clinical manifestations, with some cases initially presenting with acute pericarditis. Minoxidil, a commonly used treatment for androgenetic alopecia (AGA), has been associated with drug-induced pericarditis. A 23-year-old man with no significant medical history presented with chest pain at rest and pericardial effusion. The patient had been taking 5 mg/day of oral minoxidil for AGA; thus, drug-induced pericarditis was initially suspected. His symptoms improved with aspirin and colchicine. However, he experienced recurrent episodes of pericarditis. On the third presentation, echocardiography revealed cardiac tamponade, and pericardiocentesis showed haemorrhagic pericardial effusion with elevated tumour markers. Imaging studies supported the suspicion of a primary cardiac malignancy. Surgical biopsy confirmed the diagnosis of cardiac angiosarcoma. The patient underwent extensive tumour resection followed by adjuvant chemotherapy and proton beam therapy and was discharged without evidence of recurrence. However, metastatic recurrence subsequently developed, and he died 30 months after surgery. This case highlights the importance of considering malignancy in the differential diagnosis of recurrent pericarditis in young adults. Although minoxidil-related pericarditis was initially suspected, multimodal imaging and histopathological evaluation led to the diagnosis of cardiac angiosarcoma. Early identification and multidisciplinary management are essential in such rare presentations to improve patient outcomes.

Open article ↗



cell therapies
2026-06-22 | Mechanical forces of beating heart suppress cancer growth.

The cardiac vasculature is characterized by high pressure, high blood flow, and dense vascular branching, which may increase its exposure to circulating tumor cells (CTCs). However, both primary cardiac tumors and metastases are remarkably rare. This mechanism has remained poorly understood. A recent report by Ciucci and co-workers show that mechanical load in the heart inhibits cancer cell proliferation. Their work proposes that physiological mechanical stimuli is not merely a regulator of cancer progression, but also an intrinsic anticancer mechanism.

Open article ↗



2025-09-20 | Coincidence or Association?: Pacing for Sinus Node Dysfunction in a Newborn With a Giant Ventricular Rhabdomyoma.

Cardiac masses are rare in pediatric patients, and multimodality imaging is crucial for diagnosis. These masses can present with different arrhythmias, adding challenges to their management. We report an unusual presentation of cardiac masses in an infant with aborted sudden cardiac arrest, ST-segment elevation electrocardiography, and recurrent supraventricular tachycardia. The masses were distant from the sinoatrial node, yet we detected severe sinus node dysfunction requiring epicardial pacemaker implantation. Although the imaging suggested malignant features, tissue biopsy confirmed the diagnosis of benign rhabdomyoma. No other manifestations of tuberous sclerosis were detected. Several cases of this tumor were reported to present with arrhythmias. The management of these cases requires a multidisciplinary approach individualized for each patient. Infants with cardiac rhabdomyoma can experience severe sinus node dysfunction, irrespective of mass location, requiring pacing. Despite current advances in cardiac imaging, tissue biopsy is still the gold standard for accurate diagnosis.

Open article ↗



2025-09-15 | Durable response of primary cardiac lymphoma after autologous stem cell transplantation and sequential CAR-T therapy: a case report and literature review.

Primary cardiac lymphoma (PCL), an exceedingly rare and aggressive extranodal lymphoma confined to the heart and/or pericardium, poses significant diagnostic and therapeutic challenges with a historically dismal prognosis. We present the first documented case of PCL achieving sustained complete response (CR) through a novel therapeutic approach combining autologous hematopoietic stem cell transplantation (ASCT) with sequential tandem CD19/20 CAR-T therapy. A 55-year-old female presented with chest tightness and pericardial effusion in April 2023. The diagnostic process involved multiple modalities and analyses, culminating in a diagnosis via CT-guided mediastinal lymph node biopsy. The patient underwent several chemotherapy regimens, including combinations of rituximab and polatuzumab vedotin, R-CHOP, Pola-R-CHP, and Pola-R-DA-EPOCH, which led to symptom relief and partial response. Subsequently, ASCT was performed, followed by sequential tandem CD19/20 CAR-T therapy. As a maintenance treatment, the PD-1 inhibitor sintilimab was administered approximately every two months. The patient achieved CR at month 3 and maintained CR for one year following the CAR-T infusion. Following CAR-T therapy, the patient developed immune effector cell-associated hematologic toxicity, which was managed with granulocyte colony-stimulating factor injection and supportive care. This case illustrates the difficulties in diagnosing and treating PCL. Through the combination of ASCT and sequential tandem CD19/20 CAR-T therapy, the patient achieved sustained CR with manageable toxicity. This case demonstrates the feasibility, safety, and potential efficacy of this combination strategy in treating high-risk lymphoma. Moreover, we propose a structured algorithm that may help optimize the clinical implementation of CAR-T therapy in similar cases. Continued follow-up and broader studies are warranted to validate these findings.

Open article ↗



2025-01-31 | Resection of a cardiac lipoma and reconstruction wall of right atrium: A case report.

Cardiac lipomas are known to cause functional disturbances and symptoms by compressing adjacent tissues or organs, leading to potential complications such as dyspnea, palpitations, and cardiac arrhythmias. We report a case of a 52-year-old female with a large, well-circumscribed lipoma in the right atrium. This rare condition required a comprehensive diagnostic approach and therapeutic strategy for effective management. A 52-year-old female patient presented to the hospital with complaints of palpitations and fatigue lasting for 1 month, accompanied by the recent discovery of a cardiac mass via echocardiography over the past 2 days. In addition, she reported occasional episodes of a dry cough. Both echocardiography and cardiac computed tomography imaging revealed an isoechoic mass within the right atrium, characterized by a regular shape and close attachment to the right atrial wall, displaying noticeable mobility. Histopathological analysis following surgical intervention confirmed that the tumor was predominantly comprised of adipocytes. The patient underwent successful resection of the right atrial lipoma, followed by reconstruction of right atrium using a bovine pericardial patch under extracorporeal circulation with a beating heart. Postoperative recovery was complete, with resolution of symptoms including palpitations and fatigue. A follow-up echocardiogram on the 66th day postsurgery confirmed the absence of any residual tumor. Patients with small lipoma often remain asymptomatic. However, large or rapidly progressing tumors may elicit symptoms such as chest pain, dyspnea, and palpitations. For asymptomatic patients with small tumors, regular observation and follow-up are typically advised to monitor tumor growth and the emergence of symptoms. Conversely, patients with large tumors or overt symptoms should be recommended for prompt surgical intervention. In this case, preoperative anatomical evaluation for the lipoma involves the right atrial free wall, which is crucial to prevent excessive resection, damage to the lateral bundle branch, and subsequent postoperative cardiac dysfunction or arrhythmia, as exemplified in this patient.

Open article ↗



2024-05-29 | Incidental diagnosis of cardiac fibroma in an infant with acute viral bronchiolitis.

Pediatric cardiac tumors are rare and, among them, 90% are benign. Cardiac fibroma is the second most frequent tumor, after rhabdomyoma. The objective of this study is to report a case of cardiac fibroma diagnosed incidentally in a patient admitted with acute viral bronchiolitis. A 5-month-old male infant was admitted to the pediatric emergency department with acute viral bronchiolitis requiring hospitalization. He presented a detectable respiratory syncytial virus in oropharyngeal swab, blood test with lymphocytosis and a chest radiography revealed cardiomegaly. Further cardiologic testing was performed detecting elevation of cardiac biomarkers, an electrocardiogram with alteration of left ventricular repolarization and echocardiogram with a heterogeneous mass in the left ventricular, with areas of calcification. A chest angiotomography suggested rhabdomyosarcoma or cardiac fibroma and a magnetic resonance showed a mass, with characteristics suggesting fibroma. The final diagnosis was made after two cardiac catheterizations for biopsy of the lesion, confirming cardiac fibroma by anatomopathological examination. Because the patient had moderate to severe systolic dysfunction, he was submitted to heart transplant. One third of cardiac fibromas are asymptomatic, generally diagnosed late through tests ordered for other reasons. The gold-standard test for definitive diagnosis is biopsy. Cardiac fibroma usually does not present spontaneous regression and, in most cases, partial or total surgical resection is necessary. When tumors are unresectable, heart transplantation should be indicated. It is essential to have detailed characterization of the cardiac mass to establish the most appropriate therapeutic approach for each patient. Tumores cardíacos pediátricos são raros e, entre eles, 90% são benignos. O fibroma cardíaco é o segundo mais frequente, após o rabdomioma. O objetivo deste trabalho é relatar um caso de fibroma cardíaco, cujo diagnóstico foi incidental em um paciente internado por bronquiolite viral aguda. Lactente do sexo masculino com cinco meses foi atendido em um pronto atendimento pediátrico com quadro de bronquiolite viral aguda, necessitando de hospitalização. Em exames complementares, apresentou vírus sincicial respiratório detectável, hemograma com linfocitose, além de radiografia de tórax com cardiomegalia. Em investigação cardiológica, as enzimas cardíacas encontravam-se elevadas, o eletrocardiograma apresentava alteração de repolarização de parede lateral de ventrículo esquerdo e o ecocardiograma demonstrou massa heterogênea em ventrículo esquerdo, com áreas de calcificação. A angiotomografia de tórax sugeriu rabdomiossarcoma ou fibroma cardíaco e a ressonância magnética demonstrou massa cuja localização e características sugeriram fibroma. O diagnóstico foi conclusivo após dois cateterismos para biópsia da lesão, confirmando fibroma cardíaco pelo anatomopatológico. Em razão da disfunção sistólica moderada a grave, o paciente foi submetido a transplante cardíaco. Um terço dos fibromas cardíacos é assintomático, geralmente diagnosticado tardiamente por meio de exames solicitados por outro motivo. O padrão-ouro para o diagnóstico definitivo é a biópsia. O fibroma cardíaco não costuma apresentar regressão espontânea, sendo submetido, na maioria dos casos, a ressecção cirúrgica parcial ou total. Nos tumores irressecáveis, o transplante cardíaco deve ser indicado. A caracterização detalhada da massa cardíaca é fundamental para traçar a conduta terapêutica mais adequada para cada paciente.

Open article ↗



proteins
2026-08-26 | Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis.

Immune checkpoint inhibitor (ICI) myocarditis is a rare but frequently fatal immune-related adverse event of cancer immunotherapy. Understanding the mechanisms of this toxicity is critical to balancing treatment with maintenance of antitumor immunity. Using integrated spatial and single-cell analyses in a pharmacological murine model, we identified regional infiltration of Ly6C+ monocytes and PD-1+ CD8+ T cells in the heart that organize into fibroblast-rich immune structures, which we term tertiary T cell niches (TTCNs). TTCNs serve as hubs for T cell activation, sharing features of tertiary lymphoid structures. A TTCN gene signature was strongly enriched in cardiac tissue from patients with ICI myocarditis. Complementary T cell receptor analyses revealed clonal expansion of cardiac T cells following ICI treatment. We further identified TTCN-associated cytokines and structural proteins as candidate therapeutic targets to reduce myocardial inflammation while considering tumor control. Together, these findings suggest that cardiac tertiary immune structures play a central role in ICI myocarditis and highlight pathways that could mitigate ICI cardiotoxicity.

Open article ↗



2026-08-25 | BIN1 overexpression rescues cardiac but not skeletal muscle defects in a mouse model of caveolinopathy.

Mutations in CAV3, encoding caveolin-3, cause caveolinopathies, rare genetic disorders affecting both skeletal and cardiac muscle. Caveolin-3 contributes to T-tubule formation and excitation-contraction coupling. To date, there are no therapy for caveolinopathies. BIN1 (amphiphysin 2), a membrane-shaping protein critical for T-tubule integrity, has shown therapeutic promise in congenital myopathies and heart dysfunction. We evaluated the therapeutic impact of BIN1 overexpression in Cav-3 knockout mice, a model recapitulating key features of human caveolinopathy. We assessed skeletal and cardiac function, T-tubule morphology, mitochondria, and gene expression using histological, physiological, and molecular approaches. Results: We found Cav-3-/- mice displayed skeletal muscle weakness, T-tubule disorganization, and mitochondrial abnormalities, alongside cardiac diastolic dysfunction and myofibrillar disarray. While BIN1 overexpression failed to improve muscle strength, T-tubule structure, or fiber atrophy, it corrected nuclear positioning and partially restored mitochondrial markers in skeletal muscle. In contrast, BIN1 robustly rescued cardiac performance, restoring end-diastolic volume, cardiac output, and sarcomeric integrity. Expression profiling revealed greater dysregulation of excitation-contraction coupling and atrogene pathways in skeletal than in cardiac muscle in Cav-3-/- mice. Cavin-4, a BIN1-interacting protein and caveolar component, was selectively dysregulated in Cav-3-/- muscle, suggesting a mechanistic barrier to BIN1-mediated rescue in this tissue. These findings identify tissue-specific differences in the molecular consequences of caveolin-3 loss and demonstrate that BIN1 overexpression effectively rescues cardiac manifestations of caveolinopathy while only partially ameliorating the associated subcellular defects in skeletal muscle. Our results support BIN1 investigation as a potential target for inherited cardiomyopathies, while highlighting the need for alternative strategies in skeletal muscle.

Open article ↗



2024-10-01 | 8120 Effective Management of Neonatal Hypercalcemia in Congenital Mesoblastic Nephroma: A Case Report on the Use of Calcitonin

Abstract Disclosure: C.S. Galvez: None. K. Rifai: None. C. Moorthy: None. S. Chheda: None. M. Zerah: None. Introduction: Pediatric patients with hypercalcemia of malignancy are typically treated with hyperhydration, loop diuretics and bisphosphonates. Calcitonin, a peptide functionally antagonizes the effects of PTH. Calcitonin has limited pharmacokinetic data in neonates, especially those with Congenital Mesoblastic Nephroma (CMN), making treatment challenging with unclear safety and efficacy parameters. We present the fourth published case describing the use of calcitonin for likely PTH-rP-mediated severe hypercalcemia in a neonate with CMN. Clinical Case: A 15-day-old late preterm male, presented with lethargy, poor feeds, severe failure to thrive and a large abdominal mass. The mother is a G4P4, with good prenatal care. On admission, the patient was hypertensive (138/84 mmHg) and appeared dehydrated. Physical examination revealed a firm mass in the right abdomen crossing the midline. Serum calcium levels were 13.5 mg/dL (normal 9.0-10.9 mg/dL), with an ionized calcium 1.71 mmol/L (normal 1.15 and 1.30 mmol/L). Abdominal ultrasound showed a large, 9.1 x 8 cm dominant solid right renal mass, most likely CMN, with left-sided medullary nephrocalcinosis. Cardiac Echo and EKG were within normal limits. The patient received hydration, nicardipine (titrated to decrease blood pressure by 10-15 mmHg per day) and furosemide at 1 mg/kg/day IV q6h. Due to the persistence of hypercalcemia after 24 hours of treatment (14.7 mg/dL serum calcium with ionize of 1.81 mmol/L), the patient received one dose of calcitonin (4 units/kg subcutaneously), resulting in a decrease in serum calcium to 11.5 mg/dL in 4 hours. The patient underwent a successful radical right uretero-nephrectomy, with post-surgery improvement of neurological, cardiovascular and electrolyte status. Unfortunately, PTH-rP sample was insufficient. Pathology reported CMN of the cellular type. CMN is a rare tumor with low malignant potential, representing approximately 3% of all pediatric renal tumors. It is the most common renal neoplasm diagnosed in the first 6 months of life. The most common symptom is an abdominal mass (76%), with hypertension (19%). Hypercalcemia was reported in only 4% which can be secondary to paraneoplastic secretion of PTH or PTH-rP. Conclusion: This case represents the fourth instance of calcitonin use in a neonate with CMN to manage persistent hypercalcemia. Subcutaneous administration of calcitonin at 4 units/kg proved effective with a short onset of action (within 2 hours) and duration of 6 to 8 hours, making it a viable alternative to bisphosphonates (action around 48 hours and duration of 7 to 14 days). Calcitonin's advantages include less significant side effects and a faster resolution of complications like "Hungry bone Syndrome." The flexibility of repeated dosing every 6 hours, with the option to increase the dose, if necessary, adds to its clinical utility. Presentation: 6/3/2024

Open article ↗



2022-02-11 | Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report.

Primary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible. Available therapeutic modalities for metastatic disease include external beam radiation therapy as well as systemic treatments, namely 131I-MIBG and more recently, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. To our knowledge, this is the first case of progressive unresectable cardiac paraganglioma with intracardiac extension treated with dosimetry based personalized PRRT to be reported. This case is of particular interest since it documents for the first time the efficacy, and especially the safety of the 177Lu-DOTATATE PRRT in this precarious context for which therapeutic options are limited. A 47-year-old man with no medical history consulted for rapidly decreasing exercise tolerance. The investigation demonstrated an unresectable progressing metastatic cardiac paraganglioma with intracardiac extension. The patient was treated with personalized 177Lu-DOTATATE PRRT and showed complete symptomatic and partial anatomical responses, with a progression-free survival of 13 months. PRRT with 177Lu-DOTATATE should be considered for inoperable cardiac paraganglioma. No major hemodynamic complications were experienced. Therapy resulted in safety and substantially improved quality of life.

Open article ↗



2003-02-21 | The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.

The activation of cells that do not express the membrane bound interleukin-6 6 receptor (IL-6R) by IL-6 and the soluble IL-6 receptor (sIL-6R) is termed transsignalling. Transsignalling may be an pathogenetic factor in human diseases as diverse as multiple myeloma (MM), Castleman's disease, prostate carcinoma, Crohn's disease, systemic sclerosis, Still's disease, osteoporosis and cardiovascular diseases. IL-6 and sIL-6R may directly or indirectly enhance their own production on endothelial or bone marrow stromal cells. Positive feedback autocrine loops thus created in affected organs may either cause or maintain disease progression. In autoimmune or vasculitic disease, the ability of the IL-6/sIL-6R complex to inhibit apoptosis of autoreactive T-cells may be central to the development of tissue specific autoimmunity. The anti-apoptotic effect of the IL-6/sIL-6R complex may be involved in tumour genesis and resistance to chemotherapy. Only in rare cases, where counterregulation has failed, there is a notable systemic effect of IL-6/sIL-6R. Appropriate animal models are necessary to establish the pathogenetic role of the IL-6/sIL-6R complex. A specific treatment option for diseases influenced by the sIL-6R could be based on gp130-Fc, a soluble gp130 (sgp130) linked to the Fc-fragment of IgG1. gp130-Fc has shown efficacy in vivo in animal models of Crohn's disease.

Open article ↗



antibodies
2026-09-18 | Cardio-immuno-oncology in cardiac tumors and cardiac metastases: immune microenvironment, therapeutic opportunities, and cardiotoxicity

Primary cardiac tumors are rare, whereas cardiac metastases are more common forms of cardiac involvement in patients with advanced malignancies; both are clinically important because of their potential cardiovascular consequences. This review summarizes current evidence on the immune microenvironment, immune-evasion mechanisms, immunotherapeutic opportunities, multi-omics-based immune decoding, and cardiovascular toxicity in cardiac tumors and cardiac metastases. Cardiac myxoma is discussed as a benign primary cardiac tumor with inflammatory, cytokine-mediated, metabolic, and candidate immune-regulatory features, whereas malignant primary cardiac tumors, particularly cardiac sarcomas such as cardiac angiosarcoma, are reviewed in relation to immunosuppressive niches, macrophage-rich microenvironments, T-cell dysfunction, and heterogeneous responses to immune checkpoint inhibitors. Cardiac metastases are considered as a clinically relevant setting in which immunotherapy may be feasible for selected patients with careful cardiovascular assessment. Key mechanisms discussed include immune checkpoint pathways, tumor-associated macrophages, metabolic reprogramming, cytokine signaling, vascular abnormalities, and spatial immune organization. The review also highlights the role of single-cell sequencing, spatial transcriptomics, proteomics, metabolomics, and integrative multi-omics approaches in defining tumor-specific immune landscapes and potential biomarkers. Finally, immune checkpoint inhibitor-associated cardiotoxicity, particularly myocarditis, is discussed with emphasis on baseline cardiovascular assessment, biomarker monitoring, multimodality imaging, and multidisciplinary cardio-oncology management.

Open article ↗



2026-05-11 | A rare case of pediatric cardiac fibroma arising from the pulmonary valve and right ventricular outflow tract presenting with obstructive hemodynamics.

Primary cardiac tumors in the pediatric population are rare, and reports of cardiac fibromas diagnosed during childhood are limited. We report a pediatric case of cardiac fibroma attached to the right ventricular outflow tract (RVOT) and pulmonary valve that presented with RVOT obstruction in a 15-month-old boy who was referred for evaluation of a heart murmur. Echocardiography revealed a mobile 10-mm mass attached to the pulmonary valve that caused RVOT obstruction and elevated right ventricular pressure. Because of the risk of embolization and hemodynamic significance, surgical excision was performed. A pathological examination confirmed the diagnosis of cardiac fibroma. Although rare, pediatric cardiac tumors can cause serious complications such as embolism and arrhythmias, thus highlighting the importance of careful auscultation, detailed imaging evaluation, and appropriate surgical decision-making. Pediatric cardiac fibromas are rare and frequently asymptomatic; however, depending on their location and mobility, they may pose a significant risk of right ventricular outflow tract obstruction and embolic events. Careful cardiac auscultation, followed by timely echocardiographic assessment, is essential for early detection. Surgical intervention should be considered on the basis of hemodynamic impact rather than tumor size alone.

Open article ↗



2026-04-10 | Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee.

Thymic epithelial tumors (TETs), comprising thymomas, thymic carcinomas, and thymic neuroendocrine neoplasms, are rare prevascular (anterior) mediastinal malignancies characterized by histologic and clinical heterogeneity. Their management is complex because of overlapping pathologic features, variable clinical behavior, frequent associations with autoimmune conditions, and lack of standardized therapeutic algorithms. This review addresses current challenges across the diagnosis, management, and treatment of TETs. We outline diagnostic difficulties, including distinguishing TETs from histologic mimickers, and highlight the utility of immunohistochemical and molecular markers. Surgical considerations for early-stage disease are explored, debating thymomectomy versus complete thymectomy and optimal minimally invasive approaches, while also discussing the role of lymph node dissection and adjuvant therapy. Furthermore, this review delves into the evolving roles of immunotherapy and targeted therapy in TETs, acknowledging their potential while addressing challenges such as high rates of autoimmune disease recurrence and adverse events. The promising, albeit largely retrospective, applications of artificial intelligence in TETs, spanning diagnosis, target discovery, and prognostic modeling, are also explored as a critical area for future integration into clinical practice.

Open article ↗



2026-03-27 | An indolent course of undifferentiated pleomorphic cardiac sarcoma mimicking myxoma: A case report.

Cardiac undifferentiated pleomorphic sarcoma (UPS) is a rare and highly malignant tumor, commonly arising in the left atrium. It is associated with poor prognosis, nonspecific symptoms, and difficulty in early diagnosis. Here, we report a case of a 71-year-old woman who presented with palpitations, chest pressure, and exertional dyspnea, in whom initial cardiac magnetic resonance imaging revealed only subtle atrial septal thickening, evaluated as nonspecific, whereas follow-up imaging 2 years later showed progressive growth, ultimately interpreted as a cardiac myxoma. Surgical resection was performed, and histopathologic examination revealed a high-grade UPS with immunohistochemistry and molecular profiling supporting the diagnosis, including amplification of MDM2 and PDGFRA. No metastases were detected, and after multidisciplinary discussion a decision was made to abstain from adjuvant therapy. This case highlights the diagnostic challenge posed by cardiac UPS mimicking benign tumors such as myxoma on imaging and the importance of longitudinal imaging review and a high index of suspicion in cases with atypical radiological features of myxoma. It also raises awareness of an unusually indolent behavior of an UPS that otherwise pursues an aggressive course.

Open article ↗



2026-03-23 | Primary cardiac angiosarcoma with isolated superior vena cava syndrome: a case report.

Primary cardiac angiosarcoma is a rare and malignant tumor that most often arises in the right atrium causing significant inflow obstruction and circulatory disruption. Owing to its location, it is most often associated with symptoms similar to heart failure including lower extremity swelling, dyspnea, and chest pain. Other symptoms of venous congestion, including superior vena cava syndrome, are possible but symptoms vary widely depending on the location and size of the tumor and are rarely isolated. In this case, a 69-year-old Filipino American female presented to our facility with isolated findings of superior vena cava syndrome that were ultimately secondary to cardiac angiosarcoma. The patient developed recurrent pericardial effusions that necessitated drain placement. She was managed with medical, chemotherapeutic, and radiation therapy in the outpatient setting. She subsequently was found to have worsening of metastatic disease that resulted in her passing. Patients with cardiac angiosarcoma may present with atypical or nonspecific symptoms, such as with our patient presenting with isolated superior vena cava syndrome, and an atypical presentation may further delay the diagnosis. Late presenting cardiac angiosarcoma contributes to a worse prognosis and higher likelihood of metastasis at the time of diagnosis. Treatment typically includes chemotherapy and radiation but surgical excision, alone or in combination with other therapies, can provide the best prognosis. Early detection of cardiac angiosarcoma is crucial for improving outcomes.

Open article ↗



other
2024-11-29 | Cardiac myxomas: a review of current treatment approaches and emerging molecular therapies

Abstract Background Cardiac myxomas are the most common primary cardiac tumors, predominantly located in the left atrium. These benign tumors can obstruct blood flow, cause embolization, or produce systemic symptoms like fever. Diagnostic tools such as echocardiography play a critical role in their identification, while surgical resection remains the primary curative treatment. Although recurrence is rare, it occurs more frequently in patients with genetic predispositions, such as the Carney complex. The risk of life-threatening complications such as embolism and sudden death necessitates prompt diagnosis and management. Despite the success of surgical treatment, recent advances have introduced minimally invasive techniques and novel molecular therapies, particularly for recurrent cases. Main body The epidemiology of cardiac myxomas highlights their rarity, with an incidence of 0.5–1 per million individuals annually. They are classified based on location, morphology, and whether they are sporadic or syndromic. Histologically, they originate from multipotent mesenchymal cells and present as gelatinous or solid masses. The genetic implicants, especially in familial cases, involve certain gene mutations, disrupting signaling pathways and leading to tumorigenesis. Diagnosis primarily relies on imaging, with transthoracic echocardiography being the first-line modality. Surgical resection, typically via median sternotomy, remains the gold standard treatment with a low recurrence rate. However, emerging molecular therapies, including gene editing, epigenetic interventions, stem cell therapy, and immunotherapy, offer promising avenues for managing complex or recurrent cases even though they are mostly in conceptual and preclinical phases. These molecular approaches target specific genetic and signaling pathways involved in myxoma formation and recurrence, and though they remain in experimental stages, the advent of gene therapy in oncology makes them the next best choice to watch out for. Conclusions While surgical resection remains curative in most cases, recurrence, particularly in familial syndromes, requires vigilant monitoring and innovative treatments. Emerging molecular therapies show potential in offering personalized treatment options, although they are still inchoate. Further research is needed to improve delivery systems and minimize the challenges associated with these therapies, paving the way for more effective management strategies.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.